Medtronic Receives FDA Approval for Valiant Navion(TM) Thoracic Stent Graft System

DUBLIN — October 23, 2018 — Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt thoracic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), intramural hematomas (IMH), and aortic type B dissections (TBAD).

ASTRO 2018: African-Americans with prostate cancer respond better to radiation therapy than Caucasian men

Contrary to recent data suggesting African-Americans face a higher mortality risk from prostate cancer than Caucasian men, a new study presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting suggests African-American men may have higher cure rates when treated with radiation therapy than Caucasian men.